Skip to main content
Premium Trial:

Request an Annual Quote

Michael Gutch

Michael Gutch has joined the life sciences investment group at Miami-based HIG Ventures, the venture capital affiliate of HIG Capital.
Prior to joining HIG, Gutch was a principal with Lilly Ventures, the corporate venture capital group of Eli Lilly, where he focused on early-stage investments in biopharmaceutical companies. During this time, he also previously served as a board director for Protagonist Therapeutics and board observer for Hydra Biosciences and Calistoga Pharmaceuticals.
Prior to his time with Eli Lilly, Gutch was employed by Genentech and Spring Mill Venture Partners. He holds a PhD in cellular and molecular pathology from the State University of New York, and conducted his postdoc at the University of California, San Francisco, and Cold Spring Harbor Laboratory.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.